BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 31, 2026
Home » Authors » Tamra Sami

Articles by Tamra Sami

Australia's TGA clarifies questions surrounding audits for comparable overseas regulators

March 22, 2019
By Tamra Sami

New Zealand's CuroNZ tests neural regeneration peptides for epilepsy, Lennox-Gastaut

March 20, 2019
By Tamra Sami
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
Read More

Australia's Biomedical Translation Fund launches Respirion, funds work on antibiotic for CF patients

March 20, 2019
By Tamra Sami
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis.
Read More

Australia's Biomedical Translation Fund launches Respirion, funds work on antibiotic for CF patients

March 19, 2019
By Tamra Sami
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis.
Read More

Australia to accept conformity assessments from U.K. NBs in no-deal Brexit scenario

March 15, 2019
By Tamra Sami

New Zealand's CuroNZ tests neural regeneration peptides for epilepsy, Lennox-Gastaut

March 14, 2019
By Tamra Sami
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
Read More

Australian smart needle could reduce risk of brain hemorrhage from biopsies

March 12, 2019
By Tamra Sami

New Zealand's Volpara AI algorithms could have massive implications for breast cancer screenings

March 11, 2019
By Tamra Sami

Admedus trialing 3D tissue-engineered heart valve

March 4, 2019
By Tamra Sami

Australia looks to reduce barriers for generic drugs to enter the market

Feb. 26, 2019
By Tamra Sami
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is asking industry stakeholders for feedback on a draft guidance to reform the generic drugs market authorization process.
Read More
Previous 1 2 … 183 184 185 186 187 188 189 190 191 … 222 223 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing